What Is D-Amphetamine? Uses, Health Risks, and Effects

D-amphetamine, also called dextroamphetamine, is a prescription stimulant used primarily to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is one of the two mirror-image forms of the amphetamine molecule and is considered the more potent of the pair in terms of its effects on the central nervous system. You encounter it under brand names like Dexedrine and as one half of the mixed-amphetamine salt combination in Adderall. Once freely available over the counter for conditions ranging from depression to nasal congestion, it is now a tightly controlled substance with a well-documented profile of benefits and risks.

How D-Amphetamine Works in the Brain

D-amphetamine’s primary job is to raise the levels of two chemical messengers in the brain: dopamine and norepinephrine. It does this through several routes at once. It blocks the transporter proteins that normally vacuum dopamine and norepinephrine back into nerve cells after they have been released. It also interferes with the protein that loads dopamine into storage vesicles inside neurons, effectively pushing more dopamine out into the space between cells. On top of that, it slows down the enzymes that break these chemicals down.¹ The net result is a surge of dopamine and norepinephrine activity in brain circuits that govern attention, motivation, and executive function. That surge is what makes d-amphetamine effective for ADHD but also what makes it risky when misused.

Approved Medical Uses

The two conditions for which d-amphetamine is most commonly prescribed are ADHD and narcolepsy. In ADHD, it helps people sustain attention, resist impulsive behavior, and organize tasks. In one randomized, placebo-controlled trial of adults with ADHD, roughly 86% of those who completed treatment with dextroamphetamine were rated as responders by their clinicians, compared with about 21% on placebo.² That is a large treatment effect, though response rates in broader populations tend to be somewhat lower because clinical trials select for patients most likely to finish the study.

For narcolepsy, amphetamine-type stimulants have been a mainstay of treatment for decades, used to combat the excessive daytime sleepiness that defines the condition.³ Newer agents like modafinil have taken over as first-line options in many cases, but d-amphetamine remains a standard alternative when other medications fall short.

Historically, amphetamine’s therapeutic use was far broader. It was prescribed for depression, obesity, fatigue, and even nasal congestion before regulatory changes restricted its approved uses to ADHD and narcolepsy.⁴

D-Amphetamine vs. Methylphenidate

If you or a child has been diagnosed with ADHD, the two most common stimulant options are d-amphetamine (or a mixed-amphetamine product like Adderall) and methylphenidate (Ritalin, Concerta). On average, the two drugs produce similar improvements in ADHD symptoms. A head-to-head randomized trial in children found both stimulants achieved comparable symptom improvement with no statistically significant difference between them during initial dose-finding.⁵ Older comparisons across several stimulant formulations have reached the same conclusion: the drugs are generally equivalent at the group level.⁶

The wrinkle is individual variability. In one study that tested both drugs in the same children, each stimulant produced a favorable response in 26 of the participants, but many children responded qualitatively or quantitatively differently to the two medications.⁷ A child who does poorly on one may thrive on the other. The side-effect profiles also diverge somewhat. Over twelve months of treatment, children on dexamphetamine lost an average of about 0.84 kg while those on methylphenidate gained about 1.26 kg, a meaningful difference in appetite suppression between the two drugs.⁵

Lisdexamfetamine and the Prodrug Approach

Lisdexamfetamine (Vyvanse) is a prodrug of d-amphetamine, meaning it is pharmacologically inactive until the body converts it. After you swallow the capsule, the drug travels through the gut and into the bloodstream, where red blood cells gradually cleave off a lysine amino acid to release active d-amphetamine.⁸ This enzymatic step happens in whole blood rather than in the liver, and it imposes a natural rate limit on how quickly d-amphetamine reaches the brain. The design was intentional: by slowing the onset, lisdexamfetamine produces a smoother effect over the day and is harder to abuse by snorting or injecting, since those routes cannot bypass the conversion step in the blood. For patients and prescribers worried about misuse potential, this makes lisdexamfetamine an appealing alternative that delivers the same active molecule.

Does D-Amphetamine Actually Make Healthy People Smarter?

The idea that stimulants like d-amphetamine serve as reliable “study drugs” for healthy people is widespread on college campuses, but the evidence is surprisingly thin. A set of meta-analyses examining cognitive performance in healthy, non-sleep-deprived adults found no overall cognitive improvement from d-amphetamine across the domains tested, which included memory, attention, and executive function. By contrast, methylphenidate did show modest gains in recall, sustained attention, and inhibitory control.⁹

That does not mean d-amphetamine has zero cognitive effects in everyone. An imaging study found that d-amphetamine improved working memory in people who started with relatively low working-memory capacity but actually worsened performance in those who started with high capacity. The correlation between the drug’s effect on brain activation and its effect on performance was strong.¹⁰ This fits a well-known pattern in neuroscience: there seems to be an optimal level of dopamine for a given task, and adding more when you are already near the peak can push you past it. If your baseline is low, the drug helps. If your baseline is already fine, it can tip you into overdrive.

EEG studies add nuance. In one double-blind trial, d-amphetamine improved behavioral accuracy and reaction time on a cognitive control task. Brain recordings showed that under high-demand conditions, d-amphetamine boosted the neural signals associated with effortful attention. Under low-demand conditions, it actually suppressed them, as though the drug sharpened the brain’s allocation of resources rather than blanket-enhancing everything.¹¹ The practical takeaway is that d-amphetamine is not a simple cognitive booster for already-healthy brains. Its effects depend on the person and the difficulty of what they are trying to do.

Cardiovascular Risks With Long-Term Use

Stimulants, including d-amphetamine, increase heart rate and blood pressure acutely. Whether years of that repeated stress translate into cardiovascular disease has been a lingering concern. A large study following patients over fourteen years found that longer use of ADHD medications was associated with a gradually increasing risk of cardiovascular problems. Each additional year of use was linked to about a 4% increase in cardiovascular disease risk. The risk was steepest in the first three years, where each additional year raised the odds by about 8%, and then leveled off. The association was strongest for hypertension, with three to five years of use nearly doubling the odds.¹²

These numbers warrant context. The absolute risk of cardiovascular events in the young adult and pediatric populations that make up most ADHD patients is low to begin with, so a modest relative increase does not necessarily translate to a large absolute number of events. Still, the findings underscore why clinicians monitor blood pressure in patients on stimulants and why cardiovascular screening is part of the prescribing process. At the extreme end, case reports describe cardiomyopathy, a weakening of the heart muscle, in patients who have used amphetamine-type medications for years. The proposed mechanisms include oxidative stress, chronic sympathetic overactivity, and direct toxic effects on heart cells.¹³ Cardiomyopathy from prescription stimulants appears to be rare, but it is worth keeping on the radar, especially for patients on higher doses for many years.

Psychosis and Mania Risk

One of the more unsettling risks of prescription amphetamines is the emergence of psychosis or mania, even in people who have no prior psychiatric history beyond ADHD. A case-control study found that recent prescription amphetamine use was associated with roughly 2.7 times the odds of experiencing psychosis or mania compared with no use. The relationship was dose-dependent: at high doses (above 30 mg of dextroamphetamine equivalents), the odds jumped to about five times higher.¹⁴ This is not a common side effect at standard therapeutic doses, but the dose-response pattern is a strong signal that the drug itself plays a causal role rather than this being coincidental.

The phenomenon fits a broader pattern seen across stimulant substances. Substance-induced psychosis is well documented in clinical practice and appears to track with the severity of use.¹⁵ For patients on prescription d-amphetamine, this means that any hallucinations, paranoid thinking, or grandiosity should prompt an immediate conversation with a prescriber. The symptoms typically resolve once the drug is stopped or the dose is lowered, but they can be frightening and are occasionally mistaken for the onset of a primary psychiatric disorder.

Growth Effects in Children and Adolescents

Parents considering stimulant medication for a child with ADHD often worry about growth suppression, and there is real data behind that concern. A prospective study found that children on stimulant treatment grew at a rate of about 5.1 cm per year in height and 2.7 kg per year in weight, compared with 6.3 cm and 4.4 kg per year in matched untreated peers.¹⁶ Despite this slower growth, bone maturation was not significantly delayed, suggesting the children were still developing skeletally on schedule even if their height and weight lagged behind.

In adolescent boys, the pattern was similar. Boys aged 14 to 15 on stimulant medication were significantly shorter and lighter than controls, and higher daily doses correlated with slower height gain.¹⁷ The reassuring piece of most long-term follow-up data is that many children appear to catch up in height once medication is stopped or after puberty, though the evidence on full adult height recovery is still debated. For families, the practical consideration is usually a trade-off: a centimeter or two of growth velocity per year versus meaningful improvement in academic and social functioning. Many clinicians handle this by monitoring growth charts closely and discussing drug holidays during summers or school breaks.

Tolerance and How the Brain Adapts

A common worry among people taking d-amphetamine for ADHD is whether it will stop working over time. The neuroscience here is more reassuring than you might expect. Animal studies show that chronic stimulant exposure causes measurable brain changes, including an increase in the number of dopamine transporter proteins. In adults with ADHD who took methylphenidate for twelve months, brain imaging showed roughly a 24% increase in dopamine transporter availability, essentially the brain trying to counteract the drug’s effect.¹⁸ Despite that measured change, clinical symptom ratings remained stable throughout the year, meaning the drug kept working in practice even as the brain adjusted biochemically. The researchers speculated that the transporter increase could theoretically worsen symptoms during periods off the medication, but it did not produce clinical tolerance in the traditional sense during treatment.

This does not mean no one ever experiences a sense that their medication is less effective. Perceived tolerance can stem from life changes, worsening sleep, increased stress, or simply the novelty of the initial effect wearing off. Genuine pharmacological tolerance severe enough to render the medication useless appears to be uncommon at therapeutic doses, though it is well established in people using amphetamines recreationally at much higher levels.

Withdrawal and Dependence

Stopping d-amphetamine after regular use can produce withdrawal symptoms: fatigue, low mood, increased appetite, sleep disturbances, and irritability. These symptoms are generally not dangerous in the way that alcohol or benzodiazepine withdrawal can be, but they can be unpleasant enough to discourage people from stopping. Research on treating amphetamine withdrawal specifically is thin. A Cochrane review found only four small randomized trials, and the medications tested showed limited benefit in reducing withdrawal symptoms or cravings.¹⁹ In practice, most clinicians manage withdrawal by tapering the dose gradually rather than stopping abruptly.

The question of whether therapeutic use of d-amphetamine leads to addiction is nuanced. Physical dependence, meaning the body adapts and withdrawal occurs on cessation, develops to some degree in most people who take the drug daily for weeks or longer. Addiction, the compulsive seeking and use of a substance despite harm, is far less common in people taking prescribed doses for a legitimate condition. The distinction matters. A patient who experiences fatigue when they skip a dose is not necessarily addicted; they are physically dependent, which is a predictable pharmacological outcome. That said, the nonmedical use of prescription stimulants among young adults remains a genuine public health concern, and the drug’s potential for misuse is the main reason it carries a Schedule II classification.²⁰

D-Amphetamine During Pregnancy

For pregnant women with ADHD, the question of whether to continue stimulant medication is stressful. Early observational data seemed alarming: unadjusted analyses found roughly double the rate of autism spectrum disorder and ADHD in children exposed to amphetamines in utero. But those raw numbers were misleading. Once researchers adjusted for the mother’s own ADHD diagnosis and other factors that differ between women who take stimulants during pregnancy and those who do not, the association disappeared. A large multi-cohort study found no increased risk of any neurodevelopmental disorder in children after in utero exposure to amphetamine or dextroamphetamine.²¹

A more recent population-based cohort study and meta-analysis reinforced those findings. After adjusting for maternal psychiatric history and sociodemographic characteristics, there was no increased risk of ADHD, autism, or any neurodevelopmental disorder in exposed children compared with children whose mothers discontinued their ADHD medication before pregnancy.²² The consistent finding across studies is that the apparent raw risk is explained by confounding, particularly the genetic and environmental factors that accompany a maternal ADHD diagnosis itself. This is reassuring, though it does not address other potential pregnancy outcomes like preterm birth or low birth weight, which are separate questions with their own evidence base. The decision to continue or stop medication during pregnancy is still best made individually with a clinician.

What an Overdose Looks Like

Acute d-amphetamine overdose produces a recognizable constellation of symptoms driven by massive sympathetic nervous system activation: a racing heart, dangerously high body temperature, rapid breathing, dilated pupils, tremors, and seizures.²³ Agitation and paranoia are common as well. There is no specific antidote for amphetamine overdose. Treatment is supportive: cooling the body, controlling seizures with benzodiazepines, and managing dangerously high blood pressure or heart rhythms as they arise. The lethal dose varies enormously between individuals, and tolerance plays a large role. Someone taking the drug daily for years can survive doses that would be fatal to a stimulant-naive person. If overdose is suspected, calling emergency services immediately is critical because the cardiovascular and thermal complications can escalate quickly.

The MAO Inhibitor Interaction

One drug interaction with d-amphetamine that prescribers take very seriously is the combination with monoamine oxidase inhibitors. MAO inhibitors block the enzymes that break down dopamine and norepinephrine, the same chemicals that d-amphetamine floods into the synapse. Combining the two can produce a dangerous spike in those chemicals, leading to a hypertensive crisis, dangerously high body temperature, or serotonin syndrome. Most prescribing guidelines treat the combination as a hard contraindication, requiring a washout period of at least two weeks between stopping an MAO inhibitor and starting a stimulant. A small body of literature has explored cautious combinations using lower-risk MAO inhibitors like transdermal selegiline, but these are done with close monitoring and remain far outside standard practice.²⁴ If you are on any antidepressant, it is worth confirming with your prescriber that it is safe to combine with a stimulant, even if the antidepressant is not technically classified as an MAO inhibitor.